For a female patient requiring testosterone replacement, should I start with the 2 mg/24‑hour transdermal testosterone patch or the 5 mg/24‑hour patch?

Start with the 2 mg/24-hour testosterone patch for female patients requiring testosterone replacement

For women with hypoactive sexual desire disorder (HSDD) requiring testosterone therapy, initiate treatment with the lower-dose transdermal patch (approximately 150–300 mcg/day delivery, equivalent to the "2 mg/24-hour" formulation) rather than the higher-dose option. This approach aligns with guideline recommendations to maintain testosterone concentrations within the physiologic premenopausal female range and minimizes risk of androgen excess 1, 2.

Rationale for Lower-Dose Initiation

The 2019 Global Consensus Statement emphasizes that testosterone therapy should aim to approximate physiological testosterone concentrations for premenopausal women 1. The 2014 Endocrine Society guidelines similarly recommend against preparations that result in supraphysiologic concentrations 2.

Clinical trial evidence supports the 300 mcg/day transdermal patch dose as optimal:

• A pivotal randomized controlled trial in 447 surgically menopausal women demonstrated that the 300 mcg/day testosterone patch significantly increased sexual desire (67% vs 48% placebo, p=0.05) and frequency of satisfying sexual activity (79% vs 43%, p=0.049) 3
• The 150 mcg/day dose showed no treatment effect, while the 450 mcg/day dose was not statistically different from either 300 mcg/day or placebo 3
• Meta-analysis of seven RCTs (n=3,035) confirmed transdermal testosterone improves sexual function with acceptable androgenic side effects 4

Dosing Algorithm

Initial prescription:

• Start with 2 mg/24-hour patch (delivers approximately 150–300 mcg testosterone daily)
• Apply twice weekly to clean, dry skin of shoulders/upper arms
• Measure baseline total testosterone before starting 1, 2

Monitoring schedule:

• Recheck testosterone at 3–6 weeks to assess patient overuse and ensure levels remain in physiologic premenopausal range (typically 20–80 ng/dL total testosterone) 1, 2
• Assess clinical response and signs of androgen excess every 6 months with repeat testosterone levels 1, 2
• Discontinue if no benefit by 6 months 1

Dose adjustment:

• If inadequate response at 6 months with confirmed physiologic levels, consider increasing to 5 mg/24-hour patch
• However, evidence suggests the dose-response relationship is not linear—higher doses do not reliably produce better outcomes 3

Critical Safety Considerations

The higher-dose (5 mg/24-hour) patch carries specific risks:

• Supraphysiologic testosterone peaks increase risk of androgenic adverse events (acne, hirsutism, voice changes) 4, 5
• Guidelines explicitly recommend against preparations resulting in supraphysiologic concentrations 1
• Long-term safety data beyond 4 years remains limited 5

Common pitfalls to avoid:

• Do not use male-formulated testosterone products—these consistently produce inappropriate supraphysiologic levels in women 2, 6
• Avoid compounded "bioidentical" preparations unless FDA-approved products are unavailable, due to lack of standardization 1
• Do not prescribe testosterone for indications other than HSDD in postmenopausal women—evidence for other uses (bone health, cognition, well-being) is insufficient 2

When to Refer or Reconsider

Refer to endocrinology if:

• Testosterone levels remain subtherapeutic despite adequate dosing
• Signs of androgen excess develop (persistent acne, hirsutism, voice deepening, clitoromegaly)
• Patient has contraindications (breast cancer, cardiovascular disease, liver dysfunction)
• No approved female-specific formulation is available in your region 1

Important caveat: The evidence base for testosterone therapy in women derives primarily from postmenopausal women with surgically induced menopause and HSDD 3, 4. Extrapolation to other populations (naturally menopausal, premenopausal) requires caution and individualized risk-benefit assessment with specialist input.

The 2 mg/24-hour patch provides the best balance of efficacy and safety based on current evidence, with the option to titrate upward only if clinically indicated and testosterone levels remain physiologic 1, 3, 4.